Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2018-02-23
Target enrollment:
Participant gender:
Summary
This is an open label study with 30-day run in phase to establish baseline parameters, 90-day
treatment phase, and a 90-day withdrawal phase to determine long-term effects, duration of
treatment response, and potential effects of EPI-589 therapy on known trajectory.